Tag Archives: diabetes

Highmark Develops Initiatives to Control Drug Spending

Highmark members will receive hemophilia drugs exclusively from three specialty pharmacies

The JDRF T1D Fund Focusing on Autoimmune Pancreatic Disease

Catalyze faster development of treatments for the autoimmune pancreatic disease

Proteus Digital Health Expanding Number of Diseases Treated

Proteus Digital Health expanding number of diseases treated to include cancer, infectious diseases, or mental health disorders

WellCare is Focusing on Care for Chronic Conditions

A major component of WellCare Health Plans’ (WellCare) strategy is to continually improve the quality of care and service that are provided to members. WellCare hopes to accomplish this by focusing on preventive health, wellness, and a population health management model that brings together medical, behavioral, social, and pharmacy programs to provide quality care and […]

Outcome-Based Contracting Acceptance Grows in Market

Specialty Pharma Services

Outcome-Based Contracting Acceptance Grows in market with the concept of taking on financial risk on complex contracts as a result of market pressure combined with more familiarity. Outcome-based contracts between pharma companies and health insurers are becoming increasingly popular. In 2016, Novartis, Amgen, and Sanofi publicized risk-sharing, value-based, outcomes-based, or pay-for-performance deals, all of which vary […]

AetnaCare Boosted by Merck Collaboration

AetnaCare Boosted by Merck Collaboration: Aetna has announced AetnaCare℠, a new program designed to offer members an integrated care plan so they have the knowledge, motivation and confidence to manage their own health. Over 40% of Aetna’s medical spend currently runs through some form of value-based care model today and the company is developing programs like […]

Continuation in rising costs of specialty drugs and maybe accelerate in next 1-2 years

Gilead Sciences’ ($GILD) hep C drug Sovaldi burst onto the market, impressing doctors and patients with its benefits and outraging payers and politicians with its price. It reached blockbuster status twice over in the course of a single quarter. But instead of an aberration, a new report suggests it is a reflection of a trend that has […]